Skip to main content
. 2019 Oct 16;9(25):7889–7905. doi: 10.7150/thno.38583

Figure 5.

Figure 5

Schematic of the process of the Sipuleucel-T therapy against prostate cancer. The monocytes were harvested from the patients and treated with the fusion protein, and re-infused into the patients. The infused monocytes could differentiate to the APCs, which activated the PAP-specific CD4+ and CD8+ T cells to kill the prostate cancer cells. Reprinted with permission from ref 113. Copyright 2011 SAGE Publications.